Avalo Therapeutics AVTX EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Avalo Therapeutics’s reported figures.
Based on trailing twelve months.
The official record: Avalo Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Avalo Therapeutics's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Avalo Therapeutics's EBITDA margin?
- Avalo Therapeutics (AVTX) reported EBITDA margin of -15,497.7% in Q4 2024.
- How has Avalo Therapeutics's EBITDA margin changed year-over-year?
- Avalo Therapeutics's EBITDA margin decreased by 997.1% year-over-year, from -1,412.6% to -15,497.7%.
- What is the long-term trend for Avalo Therapeutics's EBITDA margin?
- Over 4 years (2020 to 2024), Avalo Therapeutics's EBITDA margin has grown at a 95.6% compound annual growth rate (CAGR), from -1,059.7% to -15,497.7%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.